Compare SOC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOC | CADL |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.8M | 641.2M |
| IPO Year | 2021 | 2021 |
| Metric | SOC | CADL |
|---|---|---|
| Price | $1.91 | $8.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $9.80 | ★ $22.11 |
| AVG Volume (30 Days) | ★ 7.2M | 1.0M |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.61 | ★ 58.62 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $77.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $4.35 |
| 52 Week High | $19.25 | $14.00 |
| Indicator | SOC | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 19.31 | 46.63 |
| Support Level | N/A | $7.70 |
| Resistance Level | $5.38 | $9.42 |
| Average True Range (ATR) | 0.23 | 0.61 |
| MACD | -0.10 | 0.13 |
| Stochastic Oscillator | 7.64 | 62.27 |
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.